Harpoon Therapeutics (HARP) Stock Forecast, Price & News

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

Is Harpoon Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics or view top-rated stocks.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Harpoon Therapeutics.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings results on Thursday, March, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.20. The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $7.03 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 112.69% and a negative net margin of 366.46%.
View Harpoon Therapeutics' earnings history.

What price target have analysts set for HARP?

8 Wall Street analysts have issued 1-year price targets for Harpoon Therapeutics' stock. Their forecasts range from $7.00 to $40.00. On average, they anticipate Harpoon Therapeutics' share price to reach $15.40 in the next year. This suggests a possible upside of 640.4% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:

• Ms. Georgia L. Erbez, Chief Financial Officer (Age 55, Pay $554.55k) (LinkedIn Profile)
• Dr. Natalie R. Sacks M.D., Chief Medical Offer (Age 57, Pay $633.35k)
• Ms. Julie M. Eastland M.B.A., Pres, CEO & Director (Age 58)
• Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 54)
• Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
• Ms. Rachael Lester, Sr. VP of Bus. Devel. & Corp. Strategy

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Harpoon Therapeutics' key competitors?

Some companies that are related to Harpoon Therapeutics include Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Aerie Pharmaceuticals (AERI), Social Capital Suvretta Holdings Corp. III (DNAC), Molecular Partners (MOLN), Adaptimmune Therapeutics (ADAP), AlloVir (ALVR), Innate Pharma (IPHA), Autolus Therapeutics (AUTL), Dynamics Special Purpose (DYNS), bluebird bio (BLUE), Voyager Therapeutics (VYGR), Checkmate Pharmaceuticals (CMPI), Lineage Cell Therapeutics (LCTX) and Innate Pharma (IPHYF).
View all of HARP's competitors.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.47%), Vanguard Group Inc. (3.89%), Candriam Luxembourg S.C.A. (2.40%), State Street Corp (1.34%), Tekla Capital Management LLC (0.79%) and Renaissance Technologies LLC (0.64%). Company insiders that own Harpoon Therapeutics stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche and Impact Fund (Cayman) Oncology.
View institutional ownership trends for Harpoon Therapeutics.

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, Federated Hermes Inc., Candriam Luxembourg S.C.A., Panagora Asset Management Inc., Connor Clark & Lunn Investment Management Ltd., Northern Trust Corp, and Simplex Trading LLC. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Ansbert Gadicke, and Holger Wesche.
View insider buying and selling activity for Harpoon Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was acquired by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Renaissance Technologies LLC, BlackRock Inc., State Street Corp, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., and Sequoia Financial Advisors LLC.
View insider buying and selling activity for Harpoon Therapeutics or or view top insider-buying stocks.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $2.08.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics has a market capitalization of $68.81 million and generates $23.65 million in revenue each year. The company earns $-116.72 million in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 99 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-7400 or via email at [email protected].